CAJ | 학술논문

目的:探讨罗格列酮改善脑缺血/再灌注损伤胰岛素抵抗患者的效果. 方法:60例老年2型糖尿病(T 2DM)并发脑梗死(CI)患者,按抛硬币分组法随机分为治疗组(31例)和对照组(29例);在常规治疗的基础上,治疗组患者给予罗格列酮片药物治疗,对照组患者给予二甲双胍药物治疗;治疗时间为6周;治疗前、后,分别测评两组患者的空腹血糖(FPG)、餐后2h血糖(2 HPG)、糖化血红蛋白(HbA 1 C)、收缩压( SBP)、舒张压( DBP)、总胆固醇( TC)、甘油三酯( TG)、低密度脂蛋白( LDL)、高密度脂蛋白( HDL)、空腹胰岛素( FIns)、神经功能缺损程度(CSS)及胰岛素敏感指数(ISI),比较两组预后差异. 结果:治疗前,两组患者的各项检测均无统计学差异(P>0. 05),治疗后,两组患者均较治疗前有明显变化(P<0. 05);治疗组患者的FINS、ISI、TG、TC、LDL、HDL等指标评分均优于对照组(均P<0. 01),治疗组患者的预后显著高于对照组(P<0. 01). 结论:罗格列酮在改善T2DM并发CI患者的脑缺血/再灌注损伤胰岛素抵抗和血液流变学方面,有良好的临床作用.
목적:탐토라격렬동개선뇌결혈/재관주손상이도소저항환자적효과. 방법:60례노년2형당뇨병(T 2DM)병발뇌경사(CI)환자,안포경폐분조법수궤분위치료조(31례)화대조조(29례);재상규치료적기출상,치료조환자급여라격렬동편약물치료,대조조환자급여이갑쌍고약물치료;치료시간위6주;치료전、후,분별측평량조환자적공복혈당(FPG)、찬후2h혈당(2 HPG)、당화혈홍단백(HbA 1 C)、수축압( SBP)、서장압( DBP)、총담고순( TC)、감유삼지( TG)、저밀도지단백( LDL)、고밀도지단백( HDL)、공복이도소( FIns)、신경공능결손정도(CSS)급이도소민감지수(ISI),비교량조예후차이. 결과:치료전,량조환자적각항검측균무통계학차이(P>0. 05),치료후,량조환자균교치료전유명현변화(P<0. 05);치료조환자적FINS、ISI、TG、TC、LDL、HDL등지표평분균우우대조조(균P<0. 01),치료조환자적예후현저고우대조조(P<0. 01). 결론:라격렬동재개선T2DM병발CI환자적뇌결혈/재관주손상이도소저항화혈액류변학방면,유량호적림상작용.
Objective:To explore effects of Rosiglitazone in improvement of cerebral ischemia/reperfusion injury insulin resist-ance. Methods:According to coin tossing method, 60 old age patients with T2DM and CI were randomly divided into treatment group (31 patients) and control group (29 patients). On the basis of conventional treatment, the treatment groups was given Rosiglitazone treatment, while the control group was given Metformin treatment. The treatment lasted for 6 weeks. Before and after treatment, FPG, 2hPG, HbA 1c, systolic pressure (SBP), diastolic pressure (DBP), TG, TC, LDL, HDL, FIns, CSS, and ISI of the two groups were evaluated, and the difference of prognosis of the two groups was compared. Results: Before the treatment, the scores of FPG, 2hPG, Fins, HbAIc, TG, TC, LDL, HDL, SBP, DBP, CSS, and ISI of the two groups were not statistically significantly different (P>0. 05). However, after the treatment, all scores of the two groups changed significantly more than those before the treatment (P<0. 05). The scores of FIns, ISI, TG, TC, LDL, HDL of treatment group were better than those of control group (P<0. 01), and the prognosis of treatment group was higher than that of control group (P<0. 01). Conclusions:Rosiglitazone has a good clinical applica-tion in improving cerebral ischemia/reperfusion injury insulin resistance and blood rheology.